Endeavor BioMedicines, Inc. announced that it has received $127.5 in a round of funding led by new investor AyurMaya Capital Management Fund, LP, a fund managed by Matrix Capital Management Company, LP on April 24, 2024. The transaction included participation from new investors SymBiosis Capital Management LLC, Woodline Partners LP, The Invus Group, LLC, Velosity Capital, LLC, Fidelity Management & Research Company, returning investors Tekla Capital Management LLC, Ally Bridge Group, Avidity Partners Management, L.P., Longitude Capital Management Co., LLC, Omega Fund Management, LLC, Perceptive Advisors LLC, Piper Heartland Healthcare Capital, LLC, T. Rowe Price Group, Inc., Eckuity LLC, Silver Arch Bio. This funding round was over-subscribed.

Karan Takhar will join board of directors of the company.